Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
UDP-N-acetylmuramoyl-L-alanine–D-glutamate ligase (MurD) is an essential cytoplasmic enzyme in bacteria that catalyzes the ATP-dependent addition of D-glutamic acid to UDP-N-acetylmuramoyl-L-alanine, producing UDP-N-acetylmuramoyl-L-alanine–D-glutamate, a critical step in peptidoglycan precursor biosynthesis. MurD, along with MurC, MurE, and MurF, forms a family of peptidoglycan peptide ligases responsible for sequentially adding amino acids to the glycan backbone precursor. These enzymatic steps are vital for maintaining bacterial cell wall integrity and survival. MurD's essential role in bacterial viability and absence in mammals make it an attractive and validated target for new antibacterial agents, although no clinically approved inhibitors exist yet[2][3][7]. The enzyme has been extensively studied in structural and mechanistic terms, facilitating rational drug design efforts.
Inhibition of MurD prevents the addition of D-glutamic acid to UDP-MurNAc-L-Ala, blocking peptidoglycan synthesis and leading to bacterial cell death[2][3].
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on UDP-N-acetylmuramoyl-L-alanine–D-glutamate ligase (MurD).